Engineering the gut microbiota to treat hyperammonemia.

Increasing evidence indicates that the gut microbiota can be altered to ameliorate or prevent disease states, and engineering the gut microbiota to therapeutically modulate host metabolism is an emerging goal of microbiome research. In the intestine, bacterial urease converts host-derived urea to ammonia and carbon dioxide, contributing to hyperammonemia-associated neurotoxicity and encephalopathy in patients with liver disease. Here, we engineered murine gut microbiota to reduce urease activity. Animals were depleted of their preexisting gut microbiota and then inoculated with altered Schaedler flora (ASF), a defined consortium of 8 bacteria with minimal urease gene content. This protocol resulted in establishment of a persistent new community that promoted a long-term reduction in fecal urease activity and ammonia production. Moreover, in a murine model of hepatic injury, ASF transplantation was associated with decreased morbidity and mortality. These results provide proof of concept that inoculation of a prepared host with a defined gut microbiota can lead to durable metabolic changes with therapeutic utility.

[1]  M. Holeček.  Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. , 2015, Nutrition.

[2]  F. Bushman,et al.  Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. , 2014, Gastroenterology.

[3]  A. Sanyal,et al.  Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  B. Sharma,et al.  Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  D. Ward,et al.  Draft Genome Sequences of the Altered Schaedler Flora, a Defined Bacterial Community from Gnotobiotic Mice , 2014, Genome Announcements.

[6]  R. Knight,et al.  What is the value of a food and drug administration investigational new drug application for fecal microbiota transplantation to treat Clostridium difficile Infection? , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  F. Bushman,et al.  Fungi of the Murine Gut: Episodic Variation and Proliferation during Antibiotic Treatment , 2013, PloS one.

[8]  Klaus Ley,et al.  Bacterial colonization factors control specificity and stability of the gut microbiota , 2013, Nature.

[9]  L. Ursell,et al.  Gut Microbiomes of Malawian Twin Pairs Discordant for Kwashiorkor , 2013, Science.

[10]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[11]  F. Bäckhed,et al.  Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. , 2012, Cell host & microbe.

[12]  Taane G. Clark,et al.  Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice , 2012, PLoS pathogens.

[13]  Curtis Huttenhower,et al.  Microbial Co-occurrence Relationships in the Human Microbiome , 2012, PLoS Comput. Biol..

[14]  David A. Relman,et al.  Microbiota-Targeted Therapies: An Ecological Perspective , 2012, Science Translational Medicine.

[15]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[16]  Claudia Cesaro,et al.  Rifaximin in the treatment of hepatic encephalopathy , 2011, Hepatic medicine : evidence and research.

[17]  A. Webster,et al.  Probiotics for patients with hepatic encephalopathy. , 2011, The Cochrane database of systematic reviews.

[18]  B. Finlay,et al.  Altering Host Resistance to Infections through Microbial Transplantation , 2011, PloS one.

[19]  Michael A Fischbach,et al.  Eating for two: how metabolism establishes interspecies interactions in the gut. , 2011, Cell host & microbe.

[20]  F. Bushman,et al.  Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes , 2011, Science.

[21]  K. Itoh,et al.  Design of species‐specific oligonucleotide probes for the detection of Bacteroides and Parabacteroides by fluorescence in situ hybridization and their application to the analysis of mouse caecal Bacteroides–Parabacteroides microbiota , 2011, Journal of applied microbiology.

[22]  K. Ikejima,et al.  CD1d-restricted natural killer T cells contribute to hepatic inflammation and fibrogenesis in mice. , 2011, Journal of hepatology.

[23]  S. Hapfelmeier,et al.  Intestinal bacterial colonization induces mutualistic regulatory T cell responses. , 2011, Immunity.

[24]  P. Bork,et al.  Enterotypes of the human gut microbiome , 2011, Nature.

[25]  R. Knight,et al.  Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. , 2011, Gastroenterology.

[26]  N. Grigoriadis,et al.  Cannabidiol improves brain and liver function in a fulminant hepatic failure‐induced model of hepatic encephalopathy in mice , 2011, British journal of pharmacology.

[27]  R. Guigó,et al.  Reshaping the gut microbiome with bacterial transplantation and antibiotic intake. , 2010, Genome research.

[28]  C. Guatimosim,et al.  A thioacetamide-induced hepatic encephalopathy model in C57BL/6 mice: a behavioral and neurochemical study. , 2010, Arquivos de neuro-psiquiatria.

[29]  F. Bushman,et al.  Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags , 2010, BMC Microbiology.

[30]  A. Sanyal,et al.  Predictors of the recurrence of hepatic encephalopathy in lactulose‐treated patients , 2010, Alimentary pharmacology & therapeutics.

[31]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.

[32]  P. Bork,et al.  A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.

[33]  J S Bajaj,et al.  Review article: the modern management of hepatic encephalopathy , 2010, Alimentary pharmacology & therapeutics.

[34]  David Artis,et al.  Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis , 2009, Mucosal Immunology.

[35]  Rob Knight,et al.  High-fat diet determines the composition of the murine gut microbiome independently of obesity. , 2009, Gastroenterology.

[36]  Z. Halpern,et al.  Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function , 2009, Hepatology.

[37]  Pascal Hols,et al.  Control of acute, chronic, and constitutive hyperammonemia by wild‐type and genetically engineered Lactobacillus plantarum in rodents , 2008, Hepatology.

[38]  M. Tuchman,et al.  N-carbamylglutamate Markedly Enhances Ureagenesis in N-acetylglutamate Deficiency and Propionic Acidemia as Measured by Isotopic Incorporation and Blood Biomarkers , 2008, Pediatric Research.

[39]  R. Knight,et al.  Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex , 2008, Nature Methods.

[40]  Rani H. Singh,et al.  Nutritional management of patients with urea cycle disorders , 2007, Journal of Inherited Metabolic Disease.

[41]  F. Bushman,et al.  DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations , 2007, Nucleic acids research.

[42]  M. Sakamoto,et al.  Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov. , 2006, International journal of systematic and evolutionary microbiology.

[43]  R. Knight,et al.  UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.

[44]  A. Belenguer,et al.  Protein recycling in growing rabbits: contribution of microbial lysine to amino acid metabolism , 2005, British Journal of Nutrition.

[45]  E. Purdom,et al.  Diversity of the Human Intestinal Microbial Flora , 2005, Science.

[46]  R. Hughes.  The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory , 2004, Neuroscience & Biobehavioral Reviews.

[47]  H. Zhao,et al.  Intestinal microflora in patients with liver cirrhosis. , 2004, Chinese journal of digestive diseases.

[48]  J. Saudubray,et al.  Clinical approach to inherited metabolic disorders in neonates: an overview. , 2002, Seminars in neonatology : SN.

[49]  Robert Lalonde,et al.  The neurobiological basis of spontaneous alternation , 2002, Neuroscience & Biobehavioral Reviews.

[50]  G. Bynum,et al.  Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis , 2001, American Journal of Gastroenterology.

[51]  P. Ferenci.  Treatment of hepatic encephalopathy. , 2001, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[52]  M. Regan,et al.  Incorporation of urea and ammonia nitrogen into ileal and fecal microbial proteins and plasma free amino acids in normal men and ileostomates. , 1999, The American journal of clinical nutrition.

[53]  F. Dewhirst,et al.  Phylogeny of the Defined Murine Microbiota: Altered Schaedler Flora , 1999, Applied and Environmental Microbiology.

[54]  M. Navasa,et al.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis. , 1999, Journal of hepatology.

[55]  D. Torrallardona,et al.  Microbial amino acid synthesis and utilization in rats: incorporation of 15N from 15NH4Cl into lysine in the tissues of germ-free and conventional rats , 1996, British Journal of Nutrition.

[56]  T. Alexander,et al.  Effect of three antibacterial drugs in lowering blood & stool ammonia production in hepatic encephalopathy. , 1992, The Indian journal of medical research.

[57]  R. Hausinger,et al.  Microbial ureases: significance, regulation, and molecular characterization. , 1989, Microbiological reviews.

[58]  P. Lietman,et al.  Liver disease, aminoglycoside antibiotics and renal dysfunction , 1988, Hepatology.

[59]  R. Freter,et al.  Continuous-flow cultures as in vitro models of the ecology of large intestinal flora , 1983, Infection and immunity.

[60]  J. E. Fischer,et al.  FALSE NEUROTRANSMITTERS AND HEPATIC FAILURE , 1982, The Lancet.

[61]  R. Baldessarini,et al.  False neurotransmitters and hepatic failure. , 1971, Lancet.

[62]  J. James,et al.  HYPERAMMONÆMIA, PLASMA AMINOACID IMBALANCE, AND BLOOD-BRAIN AMINOACID TRANSPORT: A UNIFIED THEORY OF PORTAL-SYSTEMIC ENCEPHALOPATHY , 1979, The Lancet.

[63]  V. Utermohlen,et al.  LYMPHOCYTE AGGLUTINATION IN MULTIPLE SCLEROSIS , 1975, The Lancet.

[64]  P. Bacon,et al.  D-PENICILLAMINE-INDUCED NEPHROPATHY , 1975, The Lancet.

[65]  M. Walser,et al.  Urea metabolism in man. , 1959, The Journal of clinical investigation.